What MACI Does — and What It Doesn't

Told you have a cartilage defect in your knee, you may be wondering whether MACI can fix it — and whether the commitment involved is worth it. The honest answer sits somewhere between those two questions.

MACI (Matrix-induced Autologous Chondrocyte Implantation) received FDA approval in 2016 for symptomatic, full-thickness cartilage defects — classified as ICRS Grade III or IV — in adult knees. The process involves two separate surgical stages: a first arthroscopic procedure harvests a small sample of healthy cartilage cells (chondrocytes) from the patient's own knee; those cells are then cultured in a laboratory and seeded onto a Type I/III collagen membrane over several weeks; a second operation implants the cell-seeded scaffold into the defect site. Because the cells come from the patient, there is no donor-matching requirement.

The technique is designed for focal, well-defined defects — typically 3 cm² or larger — in a knee that is otherwise structurally sound. It is not a treatment for widespread arthritis, and it works best when the surrounding cartilage is healthy and the joint is correctly aligned.

Critically, MACI is a joint-preservation strategy, not a cure. Its goal is to relieve pain and restore function well enough to delay or avoid knee replacement — not to halt the biological ageing of cartilage or return the knee to a pre-injury state. High-impact, cutting sports are generally discouraged after the procedure. The realistic aim is sustained improvement in daily life and moderate activity.

The two-stage surgical pathway and a recovery measured in months rather than weeks are central to any honest appraisal — both shape whether MACI is the right choice for a given patient.

Who Is a Good Candidate

Strict selection criteria are not a formality — they are the reason MACI's outcomes look as strong as they do in the published evidence. Candidacy rests on several intersecting factors, and meeting most of them is not the same as meeting all of them.

The research base is strongest for adults aged 18–55 with a single, isolated full-thickness lesion of at least 3 cm² — the size threshold at which MACI consistently outperformed microfracture in the SUMMIT trial. Healthy cartilage must surround the defect: without sound borders, the implanted scaffold has nothing structurally stable to integrate with. The knee also needs correctly aligned mechanics and intact ligaments. Both matter mechanically — malalignment concentrates load on the graft site, and ligament laxity creates shear forces that can disrupt the maturing scaffold before it consolidates.

Neither malalignment nor ligament instability is an automatic barrier to MACI. In carefully selected patients, an osteotomy to correct alignment or a ligament reconstruction can be undertaken before or alongside implantation, making MACI viable in cases where it would otherwise fail. Whether that combination is appropriate requires a specialist assessment of the whole joint picture.

For smaller defects — roughly under 2–4 cm² — the two-stage cell-based pathway is generally not warranted. Single-stage procedures such as AMIC, microfracture, or mosaicplasty carry a lighter procedural burden and have comparable short-term outcomes at those defect sizes. The evidence for MACI's superiority is most robust where those simpler options become less reliable: lesions of 3 cm² and above.

Firm contraindications include generalised (multi-compartment) osteoarthritis, active inflammatory arthritis, and any history of active joint infection. Where damage has spread beyond a focal area, cartilage restoration has no healthy baseline to work from.

Age above 55 is not an automatic exclusion, but the evidence is thinner in that cohort; published series are dominated by younger, active adults, and a specialist will weigh biological joint age alongside chronological age when assessing suitability.

What the Evidence Actually Shows

The most robust clinical evidence starts with the SUMMIT randomised controlled trial, which compared MACI directly against microfracture in patients with focal chondral defects of 3 cm² or larger. At both two and five years, a significantly greater proportion of MACI patients achieved clinically meaningful improvements in KOOS pain and function scores — a finding that established MACI as the benchmark for this defect-size range.

Longer-term, a 2024 systematic review by Wang and colleagues followed 168 patients for a minimum of ten years (range 10–17 years). Patient-reported outcome improvements proved durable across that timeframe, with an all-cause reoperation rate of 9.0% and a progression-to-total-knee-arthroplasty rate of 7.4%. That figure — fewer than one in thirteen patients requiring joint replacement over more than a decade — provides the clearest published signal that MACI meaningfully delays the arthroplasty pathway.

The counterweight comes from a prospective New Zealand series that paired serial MRI with biopsy, offering a view inside the graft that population-level outcome scores cannot provide. Graft fill declined from 90% at two years to 72% at five years and 49% at ten years; on biopsy, 73% of tissue samples showed fibrocartilage rather than the hyaline cartilage MACI theoretically regenerates, and 80% of grafts were measurably softer than surrounding articular cartilage on re-arthroscopy. Outcome scores in that cohort improved to two years, plateaued to five, then deteriorated at ten — a trajectory the population-level data alone do not reveal.

Patient-satisfaction data offer an intermediate picture. Among patients with intact grafts at long-term follow-up (Leja 2023), 74% rated their knee as 'good' or 'excellent' and 70% reported satisfaction with surgery — but intact grafts at a decade are not universal.

Taken together, the evidence does not settle a simple yes or no. Population-level PRO durability is real; so is individual graft variability. Whether a particular patient achieves sustained benefit or experiences graft deterioration depends heavily on factors such as lesion size, joint alignment, and the biological quality of surrounding tissue — which is why candidacy assessment and technical execution carry as much weight as the procedure itself.

The Two-Stage Procedure and Recovery Timeline

MACI unfolds across two distinct surgical episodes separated by several weeks — a timeline that shapes not just the operation itself but the months that follow.

The first stage is a short arthroscopic procedure to harvest a small sample of healthy chondrocytes from a low-load area of the knee. The biopsy is minimally invasive, but it marks only the beginning: those cells are sent to a specialist laboratory, where they are cultured and seeded onto a Type I/III collagen membrane over a period of several weeks. Patients go home after stage one with a relatively straightforward initial recovery, knowing the substantive surgery is still ahead.

Stage two — the implantation — is the main procedure. The cell-seeded membrane is surgically fixed into the prepared defect site and secured so the maturing chondrocytes can integrate with the surrounding tissue. Protected recovery begins in earnest from this point.

In the weeks immediately following implantation, crutch-assisted mobility shields the graft while it establishes. Full weight-bearing is reintroduced gradually according to a structured protocol — not as a fixed date, but as a staged progression tied to tissue maturation. A formal physiotherapy programme typically runs for 6–9 months, working through muscle activation, range of motion, and progressive load-bearing in sequence. Full functional recovery, including return to physically demanding work or sport, generally takes 12–18 months, reflecting the time new cartilage cells need to consolidate. Patients who expect to be active again within a few months frequently find this window the most demanding part of the whole process to accept.

Data from a 2025 gait-analysis study (35 patients, mean defect 4.2 cm², mean follow-up 42.6 months) add a layer of nuance to the recovery picture: 94.3% of patients reported satisfaction with surgery, and improvements across all patient-reported outcome measures were statistically significant. At the same time, walking speed and knee flexion angle remained measurably lower than those of healthy controls — a gap that persisted even among patients who felt well. High satisfaction and complete biomechanical normalisation are not the same thing, and setting expectations about return to high-demand movement before surgery allows patients to interpret their own recovery more accurately rather than being caught off-guard by residual asymmetry at the twelve-month mark.

How MACI Compares to Other Cartilage Repair Options

Defect size is the primary sorting criterion when choosing between MACI and its alternatives.

For lesions smaller than 2–4 cm², single-stage options are generally preferred before escalating to a two-stage cell-based pathway. Microfracture historically occupied this space, but the fibrocartilage it produces tends to break down within two to three years, and repeated marrow stimulation damages the subchondral bone plate — compromising future repair options. AMIC (autologous matrix-induced chondrogenesis), which augments microfracture with a collagen scaffold in a single operation, provides a more durable bridge technique. OATS or mosaicplasty — transferring osteochondral plugs from a low-load donor site — remains appropriate for the 1–4 cm² range where a single-stage autograft is viable and donor-site morbidity is acceptable.

At the other end of the scale, very large or post-traumatic defects that exhaust what autograft tissue can fill call for fresh osteochondral allograft (OCA), which uses donor tissue to resurface the defect without the cell-culture step.

A 2025 matched-pairs study comparing MACI, AMIC, and minced cartilage implantation in 48 patients found no statistically significant difference between the three techniques in pain, symptoms, or function at two years — all groups improved significantly from baseline. That finding does not make MACI inferior, but it does mean its two-stage procedural burden and cost are harder to justify outside the defect-size range where its evidence is strongest (lesions ≥3 cm²).

Where malalignment is present, corrective osteotomy (HTO or DFO) must be addressed before or alongside any cartilage procedure. Proceeding without correcting load distribution carries a meaningfully higher failure risk — alignment is not an optional extra.

On the innovation front, single-stage needle-delivered autologous approaches are in active development — specifically targeting the two theatre visits that define the standard MACI pathway. The NanoACi 100 study is a prospective programme currently collecting combined-protocol outcome data for one such technique: a non-arthroscopic, single-session injection delivered without arthroscopy. Until those results mature, these approaches represent a genuine design advance over the two-stage model rather than a validated clinical equivalent to established cell-based repair.

Choosing a Specialist and Next Steps

For the right candidate — a younger adult with a single focal defect of 3 cm² or larger, stable ligaments, correctly aligned mechanics, and a genuine willingness to commit to 12–18 months of structured recovery — the published evidence suggests the answer is yes. The SUMMIT trial's five-year outcome data and a 7.4% rate of progression to knee replacement across a decade both point toward a procedure that meaningfully preserves the joint in this group. For patients outside that profile — smaller lesions, concurrent instability, or generalised wear — the same evidence argues for a different first step rather than a more demanding one.

Specialist selection is the most consequential practical decision a patient can make. Experience in cell-based cartilage procedures shapes candidacy assessment and influences surgical outcomes. Useful questions to prepare for any consultation include: what the MRI confirms about lesion size and grade; whether alignment or ligament issues need addressing before implantation; what the realistic recovery arc looks like given work and life demands; and how progress will be tracked over the years that follow.

A second opinion is entirely reasonable for a two-stage procedure with this level of commitment. Specialist directories maintained by surgical professional bodies and cartilage-focused clinical services list UK-based surgeons who perform these procedures regularly — searching by region and procedure type is a practical starting point for finding an experienced clinician.